Nektar Therapeutics and Bristol-Myers Squibb were granted Breakthrough Therapy Designation by the U.S. FDA for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.    The Breakthrough Therapy Designation is based on clinical data from the cohort of patients with metastatic melanoma that were treated with the doublet therapy in the ongoin...